Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Free Report)’s share price dropped 9.1% during mid-day trading on Friday . The stock traded as low as $0.39 and last traded at $0.41. Approximately 2,947 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 27,623 shares. The stock had previously closed at $0.45.
Panbela Therapeutics Stock Down 9.1 %
The firm has a market cap of $1.99 million, a price-to-earnings ratio of -0.01 and a beta of 1.56. The stock’s 50 day moving average is $0.34 and its 200 day moving average is $0.35.
About Panbela Therapeutics
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Recommended Stories
- Five stocks we like better than Panbela Therapeutics
- Expert Stock Trading Psychology Tips
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- What Does Downgrade Mean in Investing?
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
